X4 Pharmaceuticals, Inc. (XFOR)
4.05
-0.02
(-0.49%)
USD |
NASDAQ |
Sep 02, 16:00
4.05
0.00 (0.00%)
After-Hours: 16:04
X4 Pharmaceuticals Research and Development Expense (Annual) : 72.22M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 72.22M |
| December 31, 2024 | 81.35M |
| December 31, 2023 | 70.02M |
| December 31, 2022 | 59.06M |
| December 31, 2021 | 48.76M |
| December 31, 2020 | 40.70M |
| Date | Value |
|---|---|
| December 31, 2019 | 30.16M |
| December 31, 2018 | 20.35M |
| December 31, 2017 | 28.13M |
| December 31, 2016 | 17.83M |
| December 31, 2015 | 12.71M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Sarepta Therapeutics, Inc. | 1.493B |
| Arrowhead Pharmaceuticals, Inc. | 585.26M |
| Oncolytics Biotech, Inc. | 13.31M |
| Sangamo Therapeutics, Inc. | 112.67M |
| Anixa Biosciences, Inc. | 5.071M |